Quantcast
Last updated on April 18, 2014 at 17:24 EDT

Latest Eisai Inc. Stories

2013-11-07 16:31:09

-- Collaboration to Focus on Global Commercialization and Development for Weight Management and Potential New Indications -- SAN DIEGO, Calif. and WOODCLIFF LAKE, N.J., Nov. 7, 2013 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) and Eisai Inc. announced today the expansion of the BELVIQ(®) (lorcaserin HCl) marketing and supply agreement between Arena Pharmaceuticals, Inc.'s wholly owned subsidiary, Arena Pharmaceuticals GmbH, and Eisai Inc. along with its parent company Eisai...

2013-11-01 08:27:25

Award supports vital research to understand rare and severe form of epilepsy WOODCLIFF LAKE, N.J., Nov. 1, 2013 /PRNewswire/ -- The Child Neurology Foundation (CNF) and Eisai Inc. today announced that the first annual Michael SanInocencio Lennox-Gastaut Syndrome (LGS) Research Award was presented to Maura Madou, MD, Child Neurology Fellow at University of California - San Francisco, Benioff Children's Hospital, to facilitate her research on LGS. Dr. Madou will receive a $30,000 grant...

2013-10-15 08:33:21

Expansion to Approximately 400 Sales Specialists Follows Increased Coverage of BELVIQ by Health Plans and Pharmacy Benefit Managers SAN DIEGO, Oct. 15, 2013 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) today reported that Eisai Inc. will increase its BELVIQ(®) sales force to approximately 400 representatives by December 2013, doubling the size of the sales force from when BELVIQ became available in June 2013. The expansion of the sales force, which has commenced and follows...

2013-10-15 08:33:08

BELVIQ® Sales Force to Double in Size by December 2013 WOODCLIFF LAKE, N.J., Oct. 15, 2013 /PRNewswire/ -- Eisai Inc. announced today that, as part of its long-term marketing strategy, the company will expand its sales force by adding more than 200 new contract sales representatives to its Specialty Business Unit. The representatives will focus on educating healthcare providers in the United States about BELVIQ(®), and will bring the total sales force to approximately 400 by December,...

2013-10-09 08:29:03

EXTON, Pa., Oct. 9, 2013 /PRNewswire/ -- Morphotek®, Inc., a subsidiary of Eisai Inc., announced today that the Children's Oncology Group (COG) has opened enrollment in a Phase 1 clinical study with MORAb-004 in pediatric patients with relapsed/refractory solid tumors. The open-label Phase 1 study will assess the safety, tolerability and pharmacokinetics of MORAb-004 administered in weekly intravenous infusions in pediatric patients. MORAb-004 is an investigational monoclonal...

2013-10-01 08:31:05

Eisai, CancerCare®, and Cancer Support Community(SM) Launch meal Trains(SM) sponsored by Magnolia(TM) During Breast Cancer Awareness Month; Campaign Aims to Drive 1,000 New meal Trains in October WOODCLIFF LAKE, N.J., Oct. 1, 2013 /PRNewswire/ -- Eisai Inc., along with collaborators CancerCare and Cancer Support Community, have announced meal Trains(SM) sponsored by Magnolia(TM), which aim to broaden the positive impact of providing meals to patients living with breast cancer and...

2013-09-16 08:28:29

SAN DIEGO, Sept. 16, 2013 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) today provided an update on Eisai Inc.'s marketing activities for BELVIQ(®) (lorcaserin HCl) as the US launch campaign enters its consumer phase. Beginning this month, full-page announcements communicating the availability of BELVIQ are being placed in major US magazines, including O, The Oprah Magazine. These announcements are intended to educate consumers about BELVIQ as a treatment option for weight...

2013-09-12 08:32:26

The BELIEVE EVERYDAY SUPPORTSM Program Offers Customized Lifestyle Resources and Free Membership to Top Calorie Tracking App for Use by BELVIQ® (lorcaserin HCl) CIV Patients WOODCLIFF LAKE, N.J., Sept. 12, 2013 /PRNewswire/ -- Eisai Inc. today announced the availability of the BELIEVE EVERYDAY SUPPORT(SM) program to provide free, comprehensive support and savings for BELVIQ(® )(lorcaserin HCl) CIV patients, including a customizable online portal designed to help some patients reach their...

2013-08-19 16:25:39

Epilepsy Drug Still Not Available to Patients 10 Months After FDA Approval WOODCLIFF LAKE, N.J., Aug. 19, 2013 /PRNewswire/ -- Eisai Inc. filed a petition today with the U.S. Court of Appeals for the District of Columbia asking the court to direct the Drug Enforcement Administration (DEA) to promptly schedule the company's epilepsy drug so that it can make it available to patients. (Logo: http://photos.prnewswire.com/prnh/20120413/MM87168LOGO ) FYCOMPA(TM) (perampanel), a new...

2013-08-15 08:28:32

WOODCLIFF LAKE, N.J., Aug. 15, 2013 /PRNewswire/ -- Eisai Inc. announced today the launch of a new website to provide employers with an educational resource for information about obesity management. The website, "Closing the Gap: Obesity Management for Employers," can be accessed at http://ctgobesity.com/. "We know from our research that most employers consider obesity to be a top employee health challenge," said Dave Martin, Vice President of Managed Markets, Value and Access for...